Jiaxin Zhou

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3192170/jiaxin-zhou-publications-by-year.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

50	455	10	19
papers	citations	h-index	g-index
74	683 ext. citations	4.5	3.75
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
50	Persistent enlargement of the pancreatic gland after glucocorticoid therapy increases the risk of relapse in IgG4-related autoimmune pancreatitis <i>Clinical Rheumatology</i> , 2022 , 1	3.9	1
49	Prevalence and risk factors of active tuberculosis in patients with rheumatic diseases: a multi-center, cross-sectional study in China. <i>Emerging Microbes and Infections</i> , 2021 , 10, 2303-2312	18.9	О
48	UPLC-MS based plasma metabolomics and lipidomics reveal alterations associated with IgG4-related disease. <i>Rheumatology</i> , 2021 , 60, 3252-3261	3.9	1
47	Case Fatality Risk of the First Pandemic Wave of Coronavirus Disease 2019 (COVID-19) in China. <i>Clinical Infectious Diseases</i> , 2021 , 73, e79-e85	11.6	40
46	Differences in clinical characteristics of IgG4-related disease across age groups: a prospective study of 737 patients. <i>Rheumatology</i> , 2021 , 60, 2635-2646	3.9	4
45	Rheumatic immune-related adverse events induced by immune checkpoint inhibitors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021 , 17, 178-185	1.9	12
44	Clinical characteristics and outcome of IgG4-related disease with hypocomplementemia: a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2021 , 23, 102	5.7	4
43	Comprehensive mapping of neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination 2021 ,		10
42	Kinetics of the neutralising antibody response in patients with hand, foot, and mouth disease caused by EV-A71: A longitudinal cohort study in Zhengzhou during 2017-2019. <i>EBioMedicine</i> , 2021 , 68, 103398	8.8	1
41	Characteristics and Outcomes of Coronary Artery Involvement in Polyarteritis Nodosa. <i>Canadian Journal of Cardiology</i> , 2021 , 37, 895-903	3.8	1
40	Prevalence and risk factors for left ventricular diastolic dysfunction in systemic sclerosis: a multi-center study of CRDC cohort in China. <i>Clinical Rheumatology</i> , 2021 , 40, 4589-4596	3.9	1
39	Risk and prognosis factors for systemic sclerosis with lung cancer: A single-centre case-control study in China. <i>International Journal of Clinical Practice</i> , 2021 , 75, e13819	2.9	O
38	The transfer and decay of maternal antibodies against enterovirus A71, and dynamics of antibodies due to later natural infections in Chinese infants: a longitudinal, paired mother-neonate cohort study. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, 418-426	25.5	5
37	Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2021 , 60, 2472-2477	3.9	5
36	MicroRNA-320a: an important regulator in the fibrotic process in interstitial lung disease of systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021 , 23, 21	5.7	8
35	Renal Involvement and HBV Infection Are Common in Chinese Patients With Cryoglobulinemia. <i>Frontiers in Immunology</i> , 2021 , 12, 580271	8.4	1
34	Clinical features of central nervous system involvement in patients with eosinophilic granulomatosis with polyangiitis: a retrospective cohort study in China. <i>Orphanet Journal of Rare Diseases</i> , 2021 , 16, 152	4.2	2

(2020-2021)

33	Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	41
32	Proteomic analyses of plasma-derived exosomes in immunoglobulin (Ig) G4-related disease and their potential roles in B cell differentiation and tissue damage. <i>Journal of Autoimmunity</i> , 2021 , 122, 10	02 65 5	1
31	Phenotype, function and clinical significance of innate lymphoid cells in immunoglobulin G4-related disease. <i>Rheumatology</i> , 2021 ,	3.9	1
30	Peripheral B-Cell Immunophenotyping Identifies Heterogeneity in IgG4-Related Disease. <i>Frontiers in Immunology</i> , 2021 , 12, 747076	8.4	2
29	Comparison of relapsing polychondritis patients with and without central nervous system involvement: A retrospective study of 181 patients. <i>International Journal of Immunopathology and Pharmacology</i> , 2021 , 35, 20587384211000547	3	5
28	Long-Term Outcomes of IgG4-Related Ophthalmic Disease in a Chinese IgG4-Related Disease Cohort <i>Frontiers in Medicine</i> , 2021 , 8, 784520	4.9	O
27	Ophthalmic involvement disparities in clinical characteristics of IgG4-related disease: a retrospective study of 573 patients <i>BMC Ophthalmology</i> , 2021 , 21, 447	2.3	0
26	Cardiac Involvement in Eosinophilic Granulomatosis With Polyangiitis: A Retrospective Study in the Chinese Population. <i>Frontiers in Medicine</i> , 2020 , 7, 583944	4.9	4
25	Clinical manifestations of Behæt disease in a large cohort of Chinese patients: gender- and age-related differences. <i>Clinical Rheumatology</i> , 2020 , 39, 3449-3454	3.9	3
24	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system. <i>Thoracic Cancer</i> , 2020 , 11, 829-834	3.2	3
23	Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 799-804	3.2	13
22	Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. <i>Thoracic Cancer</i> , 2020 , 11, 810-818	3.2	11
21	Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction. <i>Thoracic Cancer</i> , 2020 , 11, 1099-1104	3.2	2
20	Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. <i>Thoracic Cancer</i> , 2020 , 11, 805-809	3.2	3
19	Management of immune checkpoint inhibitor-related adverse events: A review of case reports. <i>Thoracic Cancer</i> , 2020 , 11, 498-504	3.2	6
18	Specificity, kinetics and longevity of antibody responses to avian influenza A(H7N9) virus infection in humans. <i>Journal of Infection</i> , 2020 , 80, 310-319	18.9	9
17	Case fatality risk of novel coronavirus diseases 2019 in China 2020 ,		9
16	Management of immune checkpoint inhibitor-related dermatologic adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 488-492	3.2	6

15	Management of immune checkpoint inhibitor-related rheumatic adverse events. <i>Thoracic Cancer</i> , 2020 , 11, 198-202	3.2	1
14	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. <i>Thoracic Cancer</i> , 2020 , 11, 191-197	3.2	26
13	Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity. <i>Thoracic Cancer</i> , 2020 , 11, 475-480	3.2	3
12	Use of glucocorticoids in the management of immunotherapy-related adverse effects. <i>Thoracic Cancer</i> , 2020 , 11, 3047-3052	3.2	6
11	Clinical features and long-term outcomes of Chinese patients with scleroderma renal crisis. <i>International Journal of Rheumatic Diseases</i> , 2020 , 23, 1194-1200	2.3	1
10	Serum IgE in the clinical features and disease outcomes of IgG4-related disease: a large retrospective cohort study. <i>Arthritis Research and Therapy</i> , 2020 , 22, 255	5.7	4
9	Systemic lupus erythematosus gastrointestinal involvement: a computed tomography-based assessment. <i>Scientific Reports</i> , 2020 , 10, 6400	4.9	2
8	Effectiveness and safety of interferon 🛭 a as an add-on treatment for refractory Beh 🗗 🕊 uveitis. Therapeutic Advances in Chronic Disease, 2019 , 10, 2040622319847881	4.9	6
7	Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: A prospective clinical trial. <i>International Journal of Rheumatic Diseases</i> , 2019 , 22, 1479-1488	2.3	10
6	The Clinical Features and Risk Factors of Parenchymal Neuro-Behcet Disease. <i>Journal of Immunology Research</i> , 2019 , 2019, 7371458	4.5	7
5	Differences and similarities between IgG4-related disease with and without dacryoadenitis and sialoadenitis: clinical manifestations and treatment efficacy. <i>Arthritis Research and Therapy</i> , 2019 , 21, 44	5.7	8
4	The Clinical Features, Risk Factors, and Outcome of Aneurysmal Lesions in Behcet Disease. Journal of Immunology Research, 2019 , 2019, 9198506	4.5	8
3	Tocilizumab in the treatment of severe and/or refractory vasculo-Beh⊟t disease: a single-centre experience in China. <i>Rheumatology</i> , 2018 , 57, 2057-2059	3.9	7
2	The efficacy of tocilizumab for the treatment of Chinese Takayasu arteritis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 171-175	2.2	11
1	Clinical characteristics of immunoglobulin G4-related disease: a prospective study of 118 Chinese patients. <i>Rheumatology</i> , 2015 , 54, 1982-90	3.9	135